STOCKS TELEGRAPH

Tag: HTGM Stock

  • HTC Molecular Diagnostics Inc. (HTGM) Soar on Proprietary Technology Features Expansion

    After the market closed on April 6, 2022, HTC Molecular Diagnostics Inc. (HTGM) announced new features of its proprietary HTG EdgeSeq technology. The news caused a rally in the stock as it soared by a huge 39.06%. Thus, HTGM was trending at a price of $1.78 per share in the after-hours while a heavy volume of 2.51 million shares was exchanged.

    Source: BioSpectrum

    It seems rebound energy had also a role to play as the recovery came after the stock plunged to a new low of $1.25 in the prior session.

    HTGM’s Latest Developments

    The company has improved its proprietary technology such that new sample preparations harmonization now enables miRNA and mRNA profiling without needing additional samples. The improved sample preparation protocol for its miRNA WTA (Whole Transcriptome Assay) is thus harmonized with HTP (HTG Transcriptome Panel). Therefore, using a single sample lysate, customers can process a sample with HTGM’s transcriptome panels of 20,000 gene mRNA and 20,000+ miRNA.

    Previously, full transcriptome analysis required separate tissue sections and sample preparation processes. With the completion of this harmonization, a single tissue section and one lysis method are expected to be required.

    In simple terms, the new development will allow streamlined workflow with crucial samples retention for use in other analyses.

    Molecular Diagnostic’s Role and Future

    Molecular diagnostics are used in the analysis of biomarkers for multiple ailments including contagious diseases, cancer, and chronic diseases among others. Technological advancement in the field has brought about a huge upsurge in R&D efforts in the healthcare industry. Furthermore, the outbreak of infectious diseases particularly covid-19 has also been a driver in fueled innovations and developments in the field. All the subsets of the field ranging from oncology molecular diagnostics to veterinary molecular diagnostics are deemed to grow substantially in the future. The overall molecular diagnostics market is expected to grow at a CAGR of 10.90% to USD 32.10 billion by 2027.

    HTGM’s Outlook

    The company’s recently commercialized HTP assay marked a nice chunk of 16% of its 2021 revenue just 5 months after the launch. With the strengthening of its team and the release of its first white paper featuring drug discovery through its proprietary platform on top of the latest development, HTGM is progressing well into 2022.

    Conclusion

    Increased efficiency, reduced turnaround times, simplified bioinformatics, and sample retention are some of the added benefits of HTGM’s latest development. Hence, the news of this latest feature expansion of its proprietary technology caused the stock to rally big in the after-hours on Wednesday.

  • What Motivated HTG Molecular (HTGM) Stock To Climb 8% In Recent Session?

    Shares of the life science company HTG Molecular Diagnostics Inc. (HTGM), whose mission is to advance precision medicine, has gained 8.57% in Monday’s session to $5.83. HTGM stock closed last trading session at $5.37. The trading volume recorded by HTGM stock was 0.24 million shares, which is higher than the 0.1 million shares average trading volume for the past 50 days.

    HTGM stock has gained 6.13% in the last five days but has lost -4.79% over the last month. Over the last three months, the HTGM stock price has gained 24.59 percent, and since the beginning of the year, it has gained 12.11 percent. Announcing inducement grants led to a rise in HTGM.

    HTGM Stock has announced what?

    HTGM specializes in molecular profiling utilizing next-generation sequencing or NGS. Utilizing HTG EdgeSeq technology, HTGM’s proprietary molecular profiling method, automatic, highly multiplex molecular profiling can be performed from solid or liquid samples, despite the limited amount of sample. In the long run, HTGM is used by its customers to identify biomarkers for precision medicine, understand how these discoveries translate into clinical practice, and ultimately to identify treatments.

    HTG Molecular recently announced that two incentive stock option awards were granted by HTGM’s Compensation Committee on July 13th and July 22nd, 2021.

    • In total, these awards were for the purchase of 30,000 shares of common stock by two newly hired employees who joined HTGM recently.
    • The exercise prices for these stock options are $5.85 per share and $5.42 per share, respectively, which is the closing trading price of HTGM on the date they are granted.
    • One-quarter of the shares vests on the anniversary of the vesting commencement date for both inducement awards, with the remaining 3/4th vesting over the next three years.
    • Upon vesting commencement, the balance of the shares will vest in twelve successive, equal quarterly installments on the last day of each calendar quarter, to begin on the last day of the quarter following the one-year anniversary of the applicable vesting commencement date.
    • HTGM also required the employee to maintain a service relationship with HTGM through their vesting dates in order to keep the award.
    • The stock options have a 10-year term and are subject to the terms and conditions outlined in HTGM’s 2021 Inducement Plan, approved by HTG’s Board of Directors on July 1, 2021.

    Why HTGM granted the awards?

    As part of the inducement grant of nonstatutory stock options, the awards by HTG Molecular (HTGM) are also subject to standard form agreements. As required by Nasdaq Listing Rules, the stock options were granted to new employees as inducements material to them to apply for employment with HTGM.